Cited by 787Schizophrenia research and treatmentMental Health and PsychiatryBipolar Disorder and Treatment

The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.

Neuroleptics and the Natural Course of Schizophrenia

Wyatt, R. J.·1991·Schizophrenia Bulletin

Open this paper in CoChat — free account

Abstract

To determine if neuroleptic treatment changes the natural course of schizophrenia, 22 studies were reviewed in which relatively similar patients were or were not given neuroleptics at specific times during the course of their illness. Nineteen of the studies were from first- or predominantly first-break populations. While there was little consensus among the authors of the studies reviewed, a reanalysis of the data indicates that early intervention with neuroleptics in first-break schizophrenic patients increases the likelihood of an improved long-term course. This finding is similar to that of earlier investigators who indicated there was a decrease in patients with the more severe forms of the illness following the introduction of convulsive therapies. Furthermore, there is evidence that stable schizophrenic patients whose neuroleptics are discontinued and have relapses may have a difficult time returning to their previous level of function. The findings describe in this paper have implications for both the treatment of schizophrenia and for understanding the pathophysiological processes that determine the course of the disorder.

Integrity signals

Registry

Crossref · 10.1093/schbul/17.2.325

Cites

73 of 73 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Statistical principles in experimental design.
Winer, B. J. (1962) · McGraw-Hill Book Company · doi:10.1037/11774-000 · Cited by 27,137
Dementia Praecox or the Group of Schizophrenias
(1951) · Journal of the American Medical Association · doi:10.1001/jama.1951.02920270079043 · Cited by 4,407
Dementia Praecox and Paraphrenia.
(1972) · Annals of Internal Medicine · doi:10.7326/0003-4819-76-6-1058_8 · Cited by 2,907
Statistical Methods for Survival Data Analysis.
Lachenbruch, P. A., & Lee, E. T. (1993) · Journal of the American Statistical Association · doi:10.2307/2290742 · Cited by 2,851
International Classification of Diseases, 10th Revision
Tassé, M. J., & Bush, K. (2018) · Sage eBooks · doi:10.4135/9781483392271.n276 · Cited by 1,921
Drug and Family Therapy in the Aftercare of Acute Schizophrenics
Goldstein, M. J. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770340019001 · Cited by 521
II. A Randomised Controlled Trial of Prophylactic Neuroleptic Treatment
Crow, T. J., Macmillan, J. F., Johnson, A. L., & Johnstone, E. C. (1986) · The British Journal of Psychiatry · doi:10.1192/bjp.148.2.120 · Cited by 491
Schizophrenia, just the facts
Wyatt, R. J., Alexander, R., Egan, M. F., & Kirch, D. G. (1988) · Schizophrenia Research · doi:10.1016/0920-9964(88)90034-5 · Cited by 478
Self-citation
Neuropathology of Schizophrenia
Stevens, J. R. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290100011003 · Cited by 474
Longitudinal Studies of Schizophrenic Patients
Huber, G., Gross, G., Schüttler, R., Linz, M. H., & Clemens, S. L. (1980) · Schizophrenia Bulletin · doi:10.1093/schbul/6.4.592 · Cited by 439

Show all 73 references

Sorted by citations

Items 201–300 of 787

The schizophrenia ketamine challenge study debate.
Carpenter, W. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00194-8 · Cited by 67
Antipsychotic Drugs for First-Episode Schizophrenia
Salimi, K., Jarskog, L. F., & Lieberman, J. A. (2009) · CNS Drugs · doi:10.2165/11314280-000000000-00000 · Cited by 73
Prevalence and Incidence of Schizophrenia Spectrum Disorders: Implications for Prevention
Jablensky, A. V. (2000) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/000486700219 · Cited by 71
The “Prodromal” Patient: Both Symptomatic and At-Risk
Woods, S. W., Miller, T. J., & McGlashan, T. H. (2001) · CNS Spectrums · doi:10.1017/s1092852900008609 · Cited by 67
Neurodynamics of Abnormalities in Cerebral Metabolism and Structure in Schizophrenia
Waddington, J. L. (1993) · Schizophrenia Bulletin · doi:10.1093/schbul/19.1.55 · Cited by 67
Strategies for improving adherence to second generation antipsychotics in patients with schizophrenia by increasing ease of use
BURTON, S. C. (2005) · Journal of Psychiatric Practice · doi:10.1097/00131746-200511000-00003 · Cited by 68
Lead-Time Bias Confounds Association Between Duration of Untreated Psychosis and Illness Course in Schizophrenia
Jonas, K. G., Fochtmann, L. J., Perlman, G., Tian, Y., Kane, J. M., Bromet, E. J., & Kotov, R. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19030324 · Cited by 68
The Recognition and Management of Early Psychosis
McCreadie, R. G. (2000) · Journal of Forensic Psychiatry · doi:10.1080/09585180050142679 · Cited by 68
New generation antipsychotic drugs and compliance behaviour
Voruganti, L. P., Baker, L. K., & Awad, A. G. (2008) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e3282f52851 · Cited by 67
The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation
Fleeman, N., McLeod, C., Bagust, A., Beale, S., Boland, A., Dundar, Y., Jorgensen, A., Payne, K., Pirmohamed, M., Pushpakom, S. P., et al. (2010) · Health Technology Assessment · doi:10.3310/hta14030 · Cited by 67
Maternal psychotropic medication and neonatal behavior
Auerbach, J. G., Hans, S. L., Marcus, J. H., & Maeir, S. (1992) · Neurotoxicology and Teratology · doi:10.1016/0892-0362(92)90050-k · Cited by 66
Attitude towards antipsychotics among out‐patients with schizophrenia in Nigeria
Adewuya, A. O., Ola, B. A., Mosaku, K. S., Fatoye, F., & Eegunranti, B. A. (2006) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2005.00745.x · Cited by 66
Drug Strategies and Treatment-Resistant Schizophrenia
Pantelis, C., & Barnes, T. R. E. (1996) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048679609076070 · Cited by 66
Crosstalk between endoplasmic reticulum stress and oxidative stress in schizophrenia: The dawn of new therapeutic approaches
Patel, S., Sharma, D., Kalia, K., & Tiwari, V. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.08.025 · Cited by 65
Reduction of Healthcare Resource Utilisation and Costs Following the Use of Risperidone for Patients with Schizophrenia Previously Treated with Standard Antipsychotic Therapy
Albright, P. S., Livingstone, S. W., Keegan, D. L., Ingham, M., Shrikhande, S., & LeLorier, J. (1996) · Clinical Drug Investigation · doi:10.2165/00044011-199611050-00005 · Cited by 65
Duration of untreated illness and outcome in schizophrenia: test of predictions in relation to relapse risk
Owens, D. G. C., Johnstone, E. C., Miller, P., Macmillan, J. F., & Crow, T. J. (2010) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.109.067694 · Cited by 64
Relationship between Duration of Untreated Psychosis and Intrinsic Corticostriatal Connectivity in Patients with Early Phase Schizophrenia
Sarpal, D. K., Robinson, D. G., Fales, C. L., Lencz, T., Árgyelán, M., Karlsgodt, K. H., Gallego, J. A., John, M., Kane, J. M., Szeszko, P. R., et al. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.55 · Cited by 64
Neuropsychological and neurophysiological findings in individuals suspected to be at risk for schizophrenia: preliminary results from the Basel early detection of psychosis study – Früherkennung von Psychosen (FEPSY)
Gschwandtner, U., Aston, J., Borgwardt, S., Drewe, M., Feinendegen, C., Lacher, D., Lanzarone, A., Stieglitz, R., & Riecher‐Rössler, A. (2003) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2003.00157.x · Cited by 63
Targeting synapses and myelin in the prevention of schizophrenia
Woo, T., & Crowell, A. L. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.07.022 · Cited by 62
Determinants of quality of life in first‐episode psychosis
MALLA, A. K., Norman, R. M. G., McLean, T. S., MacDonald, C., McIntosh, E., Dean‐Lashley, F., Lynch, J., Scholten, D. J., & Ahmed, R. (2003) · Acta Psychiatrica Scandinavica · doi:10.1046/j.0001-690x.2003.00221.x · Cited by 63
Anosognosia in schizophrenia: hidden in plain sight.
Lehrer, D. S., & Lorenz, J. (2014) · PubMed Central · Cited by 63
Early intervention in schizophrenia and related disorders: advantages and pitfalls
Malla, A., & Norman, R. (2002) · Current Opinion in Psychiatry · doi:10.1097/00001504-200201000-00004 · Cited by 63
Functional impairments in elderly patients with schizophrenia and major affective illness in the community: Social skills, living skills, and behavior problems
Bartels, S. J., Mueser, K. T., & Miles, K. M. (1997) · Behavior Therapy · doi:10.1016/s0005-7894(97)80033-0 · Cited by 61
Monozygotic twins discordant for schizophrenia are discordant for N-CAM and L1 in CSF
Półtorak, M., Wright, R., Hemperly, J. J., Torrey, E. F., Issa, F., Wyatt, R. J., & Freed, W. J. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00023-1 · Cited by 60
Self-citation
A systematic review of explanatory models of illness for psychosis in developing countries
Bhikha, A. G., Farooq, S., Chaudhry, N., & Husain, N. (2012) · International Review of Psychiatry · doi:10.3109/09540261.2012.711746 · Cited by 59
A 20‐year follow‐up study on schizophrenia in Singapore
Kua, J., Wong, K. E., Kua, E. H., & Tsoi, W. F. (2003) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2003.00107.x · Cited by 59
Prevalence and Course of Schizophrenia in a Chinese Rural Area
Ran, M., Xiang, M., Li, S., Shan, Y.-H., Huang, M., Li, S., Liu, Z., Chen, E. Y. H., & Chan, C. (2003) · Australian & New Zealand Journal of Psychiatry · doi:10.1046/j.1440-1614.2003.01203.x · Cited by 59
Neurobiological findings in early phase schizophrenia
Copolov, D. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00033-8 · Cited by 59
Multivariate prediction of emerging psychosis in adolescents at high risk for schizophrenia
Shah, J. L., Eack, S. M., Montrose, D. M., Tandon, N., Miewald, J. M., Prasad, K. M. R., & Keshavan, M. S. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.08.012 · Cited by 58
Neurodevelopment or neurodegeneration: review of theories of schizophrenia.
Pino, Ó., Guilera, G., Gómez‐Benito, J., Najas-García, A., Rufián, S., & Rojo, E. (2014) · Actas Españolas de Psiquiatría · Cited by 59
Remission in schizophrenia: Applying recent consensus criteria to refine the concept
Lasser, R. A., Nasrallah, H. A., Helldin, L., Peuskens, J., Kane, J. M., Docherty, J., & TOLEDOTRONCO, A. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.05.003 · Cited by 57
Validation of Polypharmacy Process Measures in Inpatient Schizophrenia Care
Janssen, B., Weinmann, S., Berger, T., & Gäebel, W. (2004) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007117 · Cited by 57
Review Do atypical antipsychotic medications favorably alter the long-term course of schizophrenia?
DeQuardo, J. R., & Tandon, R. (1998) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(98)00024-7 · Cited by 57
Drug Treatment of Schizophrenia in the 1990s
Fleischhacker, W. W., & Hummer, M. (1997) · Drugs · doi:10.2165/00003495-199753060-00002 · Cited by 57
Lack of an inverse relationship between duration of untreated psychosis and cognitive function in first episode schizophrenia
Goldberg, T. E., Burdick, K. E., McCormack, J., Napolitano, B. A., Patel, R. C., Sevy, S. M., GOLDMAN, R. S., Lencz, T., Malhotra, A. K., Kane, J. M., et al. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.11.003 · Cited by 56
The outcome of early intervention in first episode psychosis
Albert, N., & Weibell, M. A. (2019) · International Review of Psychiatry · doi:10.1080/09540261.2019.1643703 · Cited by 56
Pathways to care and treatment delays in first and multi episode psychosis
Temmingh, H. S., & Oosthuizen, P. P. (2008) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-008-0358-5 · Cited by 55
Kraepelin and psychotic prodromal conditions
Klosterkötter, J., Schultze‐Lutter, F., & Ruhrmann, S. (2008) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-008-2010-5 · Cited by 55
Hospitalization and psychosis: Influences on the course of cognition and everyday functioning in people with schizophrenia
Harvey, P. D., Loewenstein, D., & Czaja, S. J. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.10.022 · Cited by 55
The course of schizophrenic psychoses: what do we really know? A selective review from an epidemiological perspective
Riecher‐Rössler, A., & Wulf Rössler, A. (1998) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s004060050037 · Cited by 55
Impact of duration of symptoms prior to first hospitalization on acute outcome in 998 schizophrenic patients
Ronald Bottlender, A., Strauß, A., & Möller, H. (2000) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00186-3 · Cited by 55
The Role of Untreated Psychosis in Neurodegeneration: A Review of Hypothesized Mechanisms of Neurotoxicity in First-Episode Psychosis
Anderson, K. K., Voineskos, A. N., Mulsant, B. H., George, T. P., & McKenzie, K. J. (2014) · The Canadian Journal of Psychiatry · doi:10.1177/070674371405901003 · Cited by 54
The Munich 15-year follow-up study (MUFUSSAD) on first-hospitalized patients with schizophrenic or affective disorders: Assessing courses, types and time stability of diagnostic classification
Möller, H. ‐., Jäger, M., Riedel, M. J., Obermeier, M., Strauß, A., & Bottlender, R. (2010) · European Psychiatry · doi:10.1016/j.eurpsy.2010.04.012 · Cited by 58
Duration of untreated negative and positive symptoms of psychosis and cognitive impairment in first episode psychosis
Cuesta, M. J., de Jalón, E. G., Campos, M., Ibáñez, B., Sánchez-Torres, A. M., & Peralta, V. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.08.019 · Cited by 54
NEURODEVELOPMENTAL AND NEUROPROGRESSIVE PROCESSES IN SCHIZOPHRENIA
Waddington, J. L., Lane, A., Scully, P. J., Larkin, C., & O’Callaghan, E. (1998) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70364-6 · Cited by 54
Drug-Free Research in Schizophrenia: An Overview of the Controversy
Appelbaum, P. S. (1996) · IRB Ethics and Human Research · doi:10.2307/3563910 · Cited by 53
Towards More Effective Antipsychotic Treatment
Kane, J. M., & Freeman, H. L. (1994) · The British Journal of Psychiatry · doi:10.1192/s0007125000293173 · Cited by 53
Effects of antipsychotic polypharmacy on side‐effects and concurrent use of medications in schizophrenic outpatients
Hashimoto, Y., Uno, J., Miwa, T., Kurihara, M., Tanifuji, H., & Tensho, M. (2012) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2012.02376.x · Cited by 52
Predicting Drug-Free Treatment Response in Acute Psychosis From the Soteria Project
Bola, J. R., & Mosher, L. R. (2002) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006964 · Cited by 52
Efficacy and safety of long‐acting risperidone in elderly patients with schizophrenia and schizoaffective disorder
Lasser, R. A., Bossie, C. A., Zhu, Y., Gharabawi, G. M., Eerdekens, M., & Davidson, M. (2004) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1184 · Cited by 52
Are we getting any better at staying better? The long view on relapse and recovery in first episode nonaffective psychosis and schizophrenia
Taylor, M., & Jauhar, S. (2019) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125319870033 · Cited by 51
Does treatment delay predict occupational functioning in first-episode psychosis?
Norman, R. M. G., Mallal, A. K., Manchanda, R., Windell, D., Harricharan, R., Takhar, J., & Northcott, S. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2006.12.024 · Cited by 51
Research in Schizophrenia and the Discontinuation of Antipsychotic Medications
Wyatt, R. J. (1997) · Schizophrenia Bulletin · doi:10.1093/schbul/23.1.3 · Cited by 51
Self-citation
Long-term antipsychotic treatment in schizophrenia: systematic review and network meta-analysis of randomised controlled trials
Zhao, Y. J., Lin, L., Teng, M., Khoo, A. L., Soh, L. B., Furukawa, T. A., Baldessarini, R. J., Lim, B. P., & Sim, K. (2016) · BJPsych Open · doi:10.1192/bjpo.bp.115.002576 · Cited by 51
Durée de psychose non traitée : état des lieux et analyse critique
Souaiby, L., Gaillard, R., & Krebs, M. (2016) · L Encéphale · doi:10.1016/j.encep.2015.09.007 · Cited by 56
Neurotoxicity, Neuroplasticity, and Magnetic Resonance Imaging Morphometry
Mathalon, D. H., Rapoport, J. L., Davis, K. L., & Krystal, J. H. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.8.846 · Cited by 51
Association of Serum Brain-Derived Neurotrophic Factor and Duration of Untreated Psychosis in First-Episode Patients with Schizophrenia
Rizos, E., Michalopoulou, P., Siafakas, N., Stefanis, N., Douzenis, A., Rontos, I., Laskos, E., Kastania, A., Zoumpourlis, V. C., & Lykouras, L. (2010) · Neuropsychobiology · doi:10.1159/000315438 · Cited by 54
Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone
van Os, J., Bossie, C. A., & Lasser, R. A. (2004) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000122861.35081.16 · Cited by 50
Biobehavioral Treatment and Rehabilitation of Schizophrenia
Kopelowicz, A., & Liberman, R. (1995) · Harvard Review of Psychiatry · doi:10.3109/10673229509017168 · Cited by 69
Prediction of acute clinical response following a first episode of non affective psychosis: Results of a cohort of 375 patients from the Spanish PAFIP study
Crespo‐Facorro, B., de la Foz, V. O., Ayesa‐Arriola, R., Pérez‐Iglesias, R., Mata, I. F., Suárez‐Pinilla, P., Tabarés‐Seisdedos, R., & Vázquez‐Barquero, J. L. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.02.009 · Cited by 48
Informed Consent in Early Psychosis Research: National Institute of Mental Health Workshop, November 15, 2000
HEINSSEN, R. K., Perkins, D. O., Appelbaum, P. S., & Fenton, W. S. (2001) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006897 · Cited by 47
Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses
Turner, M. S., & Stewart, D. W. (2006) · Journal of Psychopharmacology · doi:10.1177/1359786806071243 · Cited by 47
Medication-Free Research in Early Episode Schizophrenia: Evidence of Long-Term Harm?
Bola, J. R. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj019 · Cited by 47
Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics
Shah, A., Xie, L., Kariburyo, F., Zhang, Q., & Gore, M. R. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0786-x · Cited by 47
Improving outcome in schizophrenia: the case for early intervention.
MALLA, A. K., Norman, R. M. G., & Voruganti, L. P. (1999) · Europe PMC (PubMed Central) · Cited by 47
Development of Risperidone PLGA Microspheres
D’Souza, S. S., Faraj, J. A., Giovagnoli, S., & DeLuca, P. P. (2014) · Journal of Drug Delivery · doi:10.1155/2014/620464 · Cited by 46
Characteristics and clinical correlates of prospective memory performance in first-episode schizophrenia
Zhou, F., Xiang, Y., Wang, C., Dickerson, F., Au, R. W. C., Zhou, J.-J., Zhou, Y., Shum, D., Chiu, H. F. K., Man, D. W. K., et al. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2011.12.001 · Cited by 46
Hypofunctional Dopamine Uptake and Antipsychotic Treatment-Resistant Schizophrenia
Amato, D., Kruyer, A., Samaha, A., & Heinz, A. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00314 · Cited by 47
Electronically monitored adherence in outpatients with schizophrenia or schizoaffective disorder: A comparison of first- vs. second-generation antipsychotics
Nakonezny, P. A., & Byerly, M. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.10.015 · Cited by 46
One hundred years of schizophrenia: A meta-analysis of the outcome literature
Hegarty, J. D., Baldessarini, R. J., Tohen, M. F., & WATERNAUX, C. M. (1993) · Schizophrenia Research · doi:10.1016/0920-9964(93)90221-4 · Cited by 48
Evaluating the Importance of Reducing the Duration of Untreated Psychosis
McGorry, P. D. (2000) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/000486700236 · Cited by 46
Associations Between Relapses and Psychosocial Outcomes in Patients With Schizophrenia in Real-World Settings in the United States
Lin, D., Joshi, K., Keenan, A., Shepherd, J., Bailey, H. M. L., Berry, M., Wright, J., Meakin, S., Benson, C. J., & Kim, E. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.695672 · Cited by 45
Minimal evidence that untreated psychosis damages brain structures: A systematic review
Anderson, K. K., Rodrigues, M., Mann, K., Voineskos, A. N., Mulsant, B. H., George, T. P., & McKenzie, K. J. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.01.021 · Cited by 47
Early intervention in psychosis: obstacles and opportunities
Singh, S. P., & Fisher, H. L. (2005) · Advances in Psychiatric Treatment · doi:10.1192/apt.11.1.71 · Cited by 113
The Risk of Medication-free Research
Carpenter, W. T. (1997) · Schizophrenia Bulletin · doi:10.1093/schbul/23.1.11 · Cited by 45
Association studies of genomic variants with treatment response to risperidone, clozapine, quetiapine and chlorpromazine in the Chinese Han population
Xu, Q., Wu, X. L., Li, M., Huang, H., Minică, C. C., Yi, Z., Wang, G., Shen, L., Xing, Q., Shi, Y., et al. (2015) · The Pharmacogenomics Journal · doi:10.1038/tpj.2015.61 · Cited by 44
White matter integrity, duration of untreated psychosis, and antipsychotic treatment response in medication-naïve first-episode psychosis patients
Kraguljac, N. V., Anthony, T., Morgan, C. J., Jindal, R. D., Burger, M. S., & Lahti, A. C. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0765-x · Cited by 44
Effectiveness of ECT Combined with Risperidone Against Aggression in Schizophrenia
Hirose, S., Ashby, C. R., & Mills, M. J. (2001) · Journal of Ect · doi:10.1097/00124509-200103000-00005 · Cited by 44
Changes in cognitive functioning following comprehensive treatment for first episode patients with schizophrenia spectrum disorders
Townsend, L. A., Norman, R. M. G., MALLA, A. K., Rychlo, A. D., & Ahmed, R. (2002) · Psychiatry Research · doi:10.1016/s0165-1781(02)00236-6 · Cited by 44
Psychopharmacologic Treatment Strategies for Depression, Bipolar Disorder, and Schizophrenia
Glick, I. D., Suppes, T. M., DeBattista, C., Hu, R. J., & Marder, S. R. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-1-200101020-00013 · Cited by 44
Early detection and treatment delay: implications for outcome in early psychosis
McGorry, P. D., Krstev, H., & Harrigan, S. (2000) · Current Opinion in Psychiatry · doi:10.1097/00001504-200001000-00007 · Cited by 44
Patients with a first episode of schizophrenia spectrum psychosis and their pathways to psychiatric hospital care in South Germany
Fuchs, J., & Steinert, T. (2004) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-004-0767-z · Cited by 42
The new antipsychotics, and their potential for early intervention in schizophrenia
Waddington, J. L., Scully, P. J., & O’Callaghan, E. (1997) · Schizophrenia Research · doi:10.1016/s0920-9964(97)00115-1 · Cited by 42
Course and outcome in schizophrenia
Fenton, W. S. (1997) · Current Opinion in Psychiatry · doi:10.1097/00001504-199701000-00009 · Cited by 42
Ethical Concerns About Relapse Studies
Shamoo, A. E., & Keay, T. J. (1996) · Cambridge Quarterly of Healthcare Ethics · doi:10.1017/s0963180100007180 · Cited by 41
Distinct effects of duration of untreated psychosis on brain cortical activities in different treatment phases of schizophrenia: A multi-channel near-infrared spectroscopy study
Chou, P., Koike, S., Nishimura, Y., Kawasaki, S., Satomura, Y., Kinoshita, A., Takizawa, R., & Kasai, K. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.11.009 · Cited by 41
Duration of Untreated Psychosis Correlates With Brain Connectivity and Morphology in Medication-Naïve Patients With First-Episode Psychosis
Maximo, J. O., Nelson, E. A., Armstrong, W. P., Kraguljac, N. V., & Lahti, A. C. (2019) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2019.10.014 · Cited by 41
Pathways to Care in a New Zealand Firstepisode of Psychosis Cohort
Turner, M., Smith-Hamel, C., & Mulder, R. (2006) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2006.01818.x · Cited by 14
Early intervention for schizophrenic disorders
Falloon, I. R. H., Coverdale, J., Laidlaw, T. M., Merry, S., Kydd, R. R., Morosini, P., & THE OTP COLLABORATIVE GROUP (1998) · The British Journal of Psychiatry · doi:10.1192/s0007125000297638 · Cited by 51
Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks
Kane, J. M., CRANDALL, D. T., Marcus, R. N., Eudicone, J. M., Pikalov, A., Carson, W. H., & Swyzen, W. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.05.009 · Cited by 40
Antipsychotic medication for early episode schizophrenia
Bola, J. R., Kao, D., Soydan, H., & Adams, C. E. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006374.pub2 · Cited by 43
Duration of Untreated Psychosis and Brain Function during Verbal Fluency Testing in First-Episode Schizophrenia: A Near-Infrared Spectroscopy Study
Chou, P., Lin, W.-H., Lin, C., Hou, P., Li, W.-R., Hung, C., Lin, C., Lan, T., & Chan, C.-H. (2015) · Scientific Reports · doi:10.1038/srep18069 · Cited by 40
Should Clozapine Be a First-line Treatment for Schizophrenia? The Rationale for a Double-Blind Clinical Trial in First-Episode Patients
Green, A. I., & Schildkraut, J. J. (1995) · Harvard Review of Psychiatry · doi:10.3109/10673229509017159 · Cited by 40
Providing treatment to prisoners with mental disorders: development of a policy
Earthrowl, M., O’Grady, J., & Birmingham, L. (2003) · The British Journal of Psychiatry · doi:10.1192/bjp.182.4.299 · Cited by 40
Abnormal serine-glycine metabolism in the brains of schizophrenics
Waziri, R., Baruah, S., & Sherman, A. D. (1993) · Schizophrenia Research · doi:10.1016/0920-9964(93)90021-a · Cited by 39
Association between duration of untreated psychosis and brain morphology in schizophrenia within the Northern Finland 1966 Birth Cohort
Penttilä, M., Jääskeläinen, E., Haapea, M., Tanskanen, P., Veijola, J. M., Ridler, K., Murray, G. K., Barnes, A., Jones, P. B., Isohanni, M. K., et al. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.08.016 · Cited by 39
Course of psychopathology, cognition and neurobiological abnormality in schizophrenia: developmental origins and amelioration by antipsychotics?
Waddington, J. L., Buckley, P. F., Scully, P. J., Lane, A., O’Callaghan, E., & Larkin, C. (1998) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(97)00012-5 · Cited by 39
Developmental trajectory and disease progression in schizophrenia: the conundrum, and insights from a 12-year prospective study in the Monaghan 101
Waddington, J. L., Scully, P. J., & Youssef, H. A. (1997) · Schizophrenia Research · doi:10.1016/s0920-9964(96)00111-9 · Cited by 39
Electroconvulsive therapy for schizophrenia
Tharyan, P., & Adams, C. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000076 · Cited by 40
Rapid tranquilization with olanzapine in acute psychosis: a case series.
Karagianis, J. L., Dawe, I. C., Thakur, A., Bégin, S., Raskin, J., & Roychowdhury, S. M. (2001) · PubMed · Cited by 38

Authors: Wyatt, R. J.
Affiliations: St. Elizabeths Hospital (US)
Corresponding author: Wyatt, R. J.
Venue: Schizophrenia Bulletin
Publisher: Oxford University Press (OUP)
Published: 1991-01-01
Volume: 17
Issue: 2
Pages: 325-351
ISSN: 0586-7614 (ISSN-L)
1745-1701
DOI: 10.1093/schbul/17.2.325
OpenAlex: W2120012268
Cited by: 787
References: 73
Citations by year: 2026: 6 · 2025: 10 · 2024: 8 · 2023: 5 · 2022: 4 · 2021: 21 · 2020: 12 · 2019: 48 · 2018: 14 · 2017: 18 · 2016: 17 · 2015: 17 · 2014: 18 · 2013: 22 · 2012: 27
FWCI: 13.18
Type: journal article
Language: en
Open access: closed
Locations: Schizophrenia Bulletin (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
Keywords: schizophrenia, antipsychotic drugs
MeSH terms: Humans, Recurrence, Schizophrenia, Time Factors, Antipsychotic Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Neuroleptics and the Natural Course of Schizophrenia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks